VERTEX PHARMACEUTICALS INC / MA Increase (Decrease) in Contract with Customer, Liability
VERTEX PHARMACEUTICALS INC / MA (VRTX) reported Increase (Decrease) in Contract with Customer, Liability of $35.68 million for the 3-month period ending 2019-03-31, per its 10-Q filed 2019-05-01.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInContractWithCustomerLiability · last filed 2019-05-01
- VERTEX PHARMACEUTICALS INC / MA increase (decrease) in contract with customer, liability for the quarter ending 2019-03-31 was $35.68M, a 8.07% decline year-over-year.
- VERTEX PHARMACEUTICALS INC / MA increase (decrease) in contract with customer, liability for the quarter ending 2018-03-31 was $38.82M.
- VERTEX PHARMACEUTICALS INC / MA increase (decrease) in contract with customer, liability for fiscal 2018 was $129.28M, a 18.69% decline from fiscal 2017.
- VERTEX PHARMACEUTICALS INC / MA increase (decrease) in contract with customer, liability for fiscal 2017 was $158.99M, a 116.55% increase from fiscal 2016.
- VERTEX PHARMACEUTICALS INC / MA increase (decrease) in contract with customer, liability for fiscal 2016 was $73.42M.
| Period end | Increase (Decrease) in Contract with Customer, Liability 3 month | Increase (Decrease) in Contract with Customer, Liability 12 month |
|---|---|---|
| 2019-03-31 | $35.68M 10-Q · filed 2019-05-01 | |
| 2018-12-31 | $129.28M 10-K · filed 2019-02-13 | |
| 2018-03-31 | $38.82M 10-Q · filed 2019-05-01 | |
| 2017-12-31 | $158.99M 10-K · filed 2019-02-13 | |
| 2016-12-31 | $73.42M 10-K · filed 2019-02-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |